Flow cytometric monitoring of the in vitro inhibition of the phosphorylation of CRKL and of SRC family kinases in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33150317" target="_blank" >RIV/61989592:15110/15:33150317 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00098892:_____/15:#0000904

Výsledek na webu

<a href="http://dx.doi.org/10.1111/ijlh.12258" target="_blank" >http://dx.doi.org/10.1111/ijlh.12258</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ijlh.12258" target="_blank" >10.1111/ijlh.12258</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Flow cytometric monitoring of the in vitro inhibition of the phosphorylation of CRKL and of SRC family kinases in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

Popis výsledku v původním jazyce

Sir, Monitoring BCR-ABL1 kinase activity by assaying CRKL phosphorylation (P-CRKL), a technique first introduced by Gorre et al, has proven to be a reliable method for the assessment of the sensitivity and/or resistance of leukemia cells from CML patients to tyrosine kinase inhibitors (TKIs) . In BCR-ABL1-positive cells, P-CRKL is inhibited by TKIs, including imatinib (IM), dasatinib (DAS) and nilotinib (NIL), in a dose-dependent manner. Originally, Western blotting with anti-CRKL antibody was used by several laboratories, including our own, to detect the change in phosphorylation of CRKL. These assays usually involve in vitro analyses of mononuclear cells in which the status of BCR-ABL1 kinase inhibition induced by TKI is measured, or in vivo analysesusing freshly drawn samples. A predictive value was established for the extent of inhibition (e.g., for 50% reduction) of P-CRKL from baseline during a defined time interval of treatment. Later, a flow cytometry method to measure in vivo

Název v anglickém jazyce

Flow cytometric monitoring of the in vitro inhibition of the phosphorylation of CRKL and of SRC family kinases in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors

Popis výsledku anglicky

Sir, Monitoring BCR-ABL1 kinase activity by assaying CRKL phosphorylation (P-CRKL), a technique first introduced by Gorre et al, has proven to be a reliable method for the assessment of the sensitivity and/or resistance of leukemia cells from CML patients to tyrosine kinase inhibitors (TKIs) . In BCR-ABL1-positive cells, P-CRKL is inhibited by TKIs, including imatinib (IM), dasatinib (DAS) and nilotinib (NIL), in a dose-dependent manner. Originally, Western blotting with anti-CRKL antibody was used by several laboratories, including our own, to detect the change in phosphorylation of CRKL. These assays usually involve in vitro analyses of mononuclear cells in which the status of BCR-ABL1 kinase inhibition induced by TKI is measured, or in vivo analysesusing freshly drawn samples. A predictive value was established for the extent of inhibition (e.g., for 50% reduction) of P-CRKL from baseline during a defined time interval of treatment. Later, a flow cytometry method to measure in vivo

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT12218" target="_blank" >NT12218: Individualizovaná léčba chronických myeloproliferativních stavů a myelodysplastického syndromu - studie buněčné metabolomiky</a><br>

Návaznosti

S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Laboratory Hematology

ISSN

1751-553X

e-ISSN

—

Svazek periodika

37

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

"e11"-"e15"

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—